We report here the first identified case of T‐cell prolymphocytic leukaemia (T‐PLL) with BRAF V600E mutation. Our patient, having progressed through standard of care treatments, was trialled on novel treatments including dasatinib, venetoclax and vemurafenib. In the setting of advanced disease, vemurafenib therapy showed some promise in our patient before he ultimately expired due to other complications.